J&J beats Wall Street estimates
Johnson & Johnson beat second-quarter profit and revenue estimates, boosted by strong sales of its drugs, including cancer treatment Darzalex and psoriasis blockbuster Stelara. The drug and device maker’s shares rose 1.4 per cent to $153.15.
ENTRADAS POPULARES
UK sets new climate target for 2035
noviembre 13, 2024
Children go back to school after Valencia floods
noviembre 13, 2024
Researchers document huge decline in African elephants
noviembre 13, 2024
Mission: Impossible 8 title revealed
noviembre 13, 2024
TRANSMISIÓN EN VIVO